Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

A cell therapy developer with operations at the Philadelphia Navy Yard plans reduce its headcount by 33% next year as it ...

The new analysis, when stratified by cancer type, reveals a response rate of 41% (14/34) in synovial sarcoma and 43% (13/30) ...

But three years later it was discovered he had a rare and aggressive synovial sarcoma tumour, which had spread to his lungs. Now 26 and cancer-free, Mr Spencer said: "It took 941 days for me to be ...

Within the next couple of weeks, the first blood samples from patients will arrive at the loading dock of Adaptimmune, a ...

Charity worker Darrell McDonald, diagnosed with rare sarcoma after a misdiagnosis, is campaigning for improved GP training to ...

The NHS has been approached for comment. "Parents and families should be able to access immediate psychological support when their child receives a cancer diagnosis, and this support should be ongoing ...

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first ...

MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...